OSR Health, Inc. is facing significant challenges after the Nasdaq Hearings Panel decided to delist its securities due to non-compliance with minimum bid price requirements. This decision, effective October 23, 2026, comes after the company's stock was suspended from trading on Nasdaq since August 26, 2026. The company is now quoted on the over-the-counter (OTC) market under the symbols OSRH and OSRHW.

The delisting is a critical event for OSR Health, which operates in the surgical and medical instruments industry. The company is currently evaluating its options to regain compliance with Nasdaq listing standards, and it aims to provide an update on its plans by November 6, 2026.

OSR Health, Inc., incorporated in Delaware, is classified under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. The company trades on the OTC market and has previously been listed on Nasdaq under the ticker OSRH. The recent filing, dated October 28, 2026, reveals the company's ongoing efforts to address its compliance issues.

According to the filing, the company received a written decision from the Nasdaq Hearings Panel on October 23, denying its request for continued listing. The decision was based on OSR Health's failure to meet the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Following this, the company has been exploring its options, including potential strategic and corporate alternatives.

In a press release accompanying the filing, CEO Peter Hwang emphasized the importance of the company's listed status. He stated, “In our Hub-and-Spoke business structure, the listed status of the Hub matters, and we are evaluating our pathway to regaining our listing.” Hwang expressed optimism about the company's pipeline and funding efforts, indicating that OSR Health is committed to returning to a national exchange based on the strength of its business.

The company has also confirmed that its $15 million funding mechanism related to its VXM01 project remains in place, which could provide essential financial support as it navigates these challenges. OSR Health has opted not to pursue a reverse stock split, believing that its share price should reflect the company's business progress rather than a mere adjustment in share count.

As OSR Health works through this transitional phase, the implications for the surgical and medical instruments industry could be significant. Competitors may view this as an opportunity to capture market share while OSR Health seeks to stabilize its operations and regain compliance.

The filing does not specify what steps will be taken next beyond the anticipated update by November 6, 2026. However, the company’s commitment to its Shareholder Loyalty Program and ongoing evaluation of its business strategy signals its intent to maintain shareholder confidence during this challenging period.